Endoxifen, a protein kinase C inhibitor and selective estrogen receptor modulator, originally used in breast cancer treatment, has recently emerged as a potential therapeutic option for managing manic episodes in bipolar disorder. This evidence concerns the gene ESR1 and manic or hypomanic episode.